Physician profile
Marc E Magod
NPI 1467533745
$4,217.45
in general payments reported to CMS, 2019-2025
31 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $342 · 2021: $243 · 2022: $549 · 2023: $694 · 2024: $789 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.89 | 2019-2025 | |
| Janssen Biotech, INC. | $459.11 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.69 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Celgene Corporation | $217.28 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $213.81 | 2024-2025 | Ibsrela |
| Pfizer INC. | $211.34 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $168.41 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $163.03 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $115.02 | 2022-2023 | Watchman Flx |
| W. L. Gore & Associates, INC. | $114.97 | 2019 | |
| Genzyme Corporation | $101.09 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.10 | 2019-2024 | Dificid |
| Amgen INC. | $92.86 | 2024-2025 | Uplizna |
| Nestle Healthcare Nutrition INC. | $91.30 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $78.29 | 2023-2024 | Idacio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $70.96 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $60.03 | 2019-2023 | Ocaliva |
| Shionogi INC | $56.60 | 2019 | |
| Ucb, INC. | $55.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.96 | 2022-2024 | Dupixent |
| Ultragenyx Pharmaceutical INC. | $49.09 | 2024 | Dojolvi |
| Madrigal Pharmaceuticals | $44.52 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals Lp | $33.91 | 2022-2023 | |
| Daiichi Sankyo INC. | $29.61 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $28.99 | 2023 | Sutab |
| Celltrion USA INC. | $26.77 | 2024 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $25.88 | 2019-2022 | |
| Shire North American Group INC | $24.88 | 2019 | |
| Organon LLC | $17.18 | 2023 | Renflexis |
| Novo Nordisk INC | $16.64 | 2024 | Wegovy |
| Covidien Lp | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Magod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.